Skip to main content
. 2021 Feb 5;13(2):120. doi: 10.3390/toxins13020120

Table 11.

Studies on the use of BoNT-A in psoriasis. RCT, randomized clinical trial; VAS, Visual Analogue Scale; TCS Total Clinical Score.

First Author [Ref.], year Type of Study n (Type of Psoriasis) BoNT-A Doses Retreatment Follow-Up Results
Zanchi [178], 2008 Observational, no RCT 15 (inverse psoriasis) 50-100 U Not reported 12 weeks Improvement in VAS scale score; photographic assessment with improvement of erythema, infiltration (87%)
Saber [181], 2011 Case report 1 (inverse psoriasis and hyperhidrosis) 100 U per axilla No 4 weeks Greatly improved (photographic documentation)
Gilbert [182], 2014 Case report 1 (plaque psoriasis) 30 U for a single plaque No 8 months Complete remission but recurrence after 8 months.
Todberg [186], 2018 Exploratory, multicenter, randomized double-blinded trial (BoNT-A vs. vehicle). 8 (plaque psoriasis) 36 U for a single plaque No 8 weeks No clinical or histological differences from the vehicle
Aschenbeck [179], 2018 Open-label pilot study 8 (plaque psoriasis) Variable number of units per plaque (average units, 53; range, 25–92) No 10 weeks PASI and BSA reduction
González [185], 2018 Descriptive cross-sectional study 8 (plaque psoriasis) Variable number of units per plaque (maximum 50 U) No 4 weeks All parameters evaluated (desquamation, erythema and infiltration) for TCS score showed improvement